AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05460793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopy-guided surgery
Description: The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
Study NCT05143996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-049
Description: \[FLT3\] x \[CD3\] bispecific T cell engager
Study NCT05406765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Injection
Description: One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
Study NCT05406765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
Study NCT04974567 — intervention group
Intervention type: OTHER
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study NCT05629793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental tests
Description: Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
Study NCT04672967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BioROSA MAP test
Description: The BioROSA MAP test is a blood test that is being developed to predict ASD risk
Study NCT05527613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whatsapp application with oral hygiene reminder for orthodontic patients
Description: Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
Study NCT05527613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whatsapp application with oral hygiene reminder for orthodontic patients
Description: Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
Study NCT04747561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PEG3-FPN
Description: For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
Study NCT05180851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant L-IFN adenovirus injection
Description: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
Study NCT04790357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current guidelines
Description: doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
Study NCT04790357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cc-MRI
Description: of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
Study NCT05452525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 I
Description: 1 tablet administration under fed condition
Study NCT05452525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379 II
Description: 1 tablet administration under fed condition
Study NCT05452525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition
Study NCT04018105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) with or without metformin
Description: Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
Study NCT04018105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) with or without metformin
Description: Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
Study NCT06214923 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RelieVRx
Description: Participants will use RelieVRx daily for 20min/day for 3 weeks
Study NCT06214923 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham-VR
Description: Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks
Study NCT06214923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-VR (natural history control)
Description: Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
Study NCT06510790 — intervention group
Intervention type: DEVICE
Intervention: Double J stent
Description: Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
Study NCT06334107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
Study NCT05849545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Garston tool
Description: GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
Study NCT05849545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Re-education
Description: General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
Study NCT05625815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 001) to (816-v1 050)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05625815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype (816-v1 051) to (816-v1 100)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05625815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 101) to (816-v1 150)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05625815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 151) to (816-v1 200)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05882604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna Injection
Description: 1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
Study NCT05882604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis with ringer solution
Description: Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
Study NCT05068076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfluorobutane
Description: Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
Study NCT05274009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cooling (control)
Description: Participants are exposed to 35°C, 60% relative humidity for 8 hours.
Study NCT05274009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended cooling
Description: Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
Study NCT05274009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid cooling
Description: Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
Study NCT04695197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 >=35 80 + 480; Twice daily for 3 days (total, six doses)
Study NCT04695197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Description: Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 >=65 720 + 240; Once-daily for 3 days (total, three doses).
Study NCT04987294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
Study NCT04987294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study NCT05297851 — intervention group
Intervention type: DRUG
Intervention: Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
Description: 10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
Study NCT05297851 — intervention group
Intervention type: DRUG
Intervention: Control
Description: Standard treatment accordind to the routine clinical practice
Study NCT04863261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
Description: The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
Study NCT05825586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distilled waters based eye drops
Description: Distilled Waters (DW)-based eyedrops
Study NCT04302142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilation with critical intracuff pressure (Pcr)
Description: Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
Study NCT04302142 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilation with critical intracuff pressure (Pcr)
Description: Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
Study NCT06318195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed Internet delivered prolonged exposure (CIPE)
Description: Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
Study NCT06451094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US therapy
Description: 3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
Study NCT05234190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QEL-001
Description: QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
Study NCT06392867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta-burst stimulation (iTBS)
Description: iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en_eur/products/magpro-x100/ ) and a Cool-B70 A/P Butterfly Coil, available at each participating centre.
Study NCT06392867 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta-burst stimulation (iTBS)
Description: iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en_eur/products/magpro-x100/ ) and a Cool-B70 A/P Butterfly Coil, available at each participating centre.
Study NCT05249803 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Patients with COVID-19 Pneumonia
Description: Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
Study NCT06229808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional Birthing ball
Description: In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women).
Study NCT05221489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to lullabies or self-selected music
Description: listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
Study NCT04591873 — intervention group
Intervention type: OTHER
Intervention: telemedicine
Description: Using telemedicine system to communicate
Study NCT04591873 — intervention group
Intervention type: OTHER
Intervention: traditional communication tools
Description: Use telephone or direct verbal communication
Study NCT05049642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
Study NCT05321589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: impression techniques for implant used for maxillary screw retained hybrid prosthesis
Description: conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done
Study NCT06451094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR
Description: Transfer Energy Capacitative and Resistive Therapy